Kisha Gulley was once kicked out of a Facebook group for mothers with autistic children after a c...Read More
The Ankylosing Spondylitis market size is anticipated to increase during the forecast period owing to the launch of several new products with novel mechanisms of action for Ankylosing Spondylitis treatment, including anti-IL17A, JAK inhibitors, and biologics. Moreover, private and government organizations have taken certain initiatives to raise awareness about the disease. Last year, the Spondylitis Association of America (SAA) officially celebrated SpA Awareness.
, /PRNewswire/ -- DelveInsight's Ankylosing Spondylitis Market Insights report includes a comprehensive understanding of current treatment practices, Ankylosing Spondylitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Ankylosing Spondylitis Market Report
Discover more about therapies set to grab major Ankylosing Spondylitis market share at Ankylosing Spondylitis Market Landscape
Ankylosing Spondylitis Overview
Ankylosing Spondylitis, commonly known as Bechterew's disease, is a common inflammatory rheumatic disease that affects the axial skeleton. Ankylosing Spondylitis causes typical inflammatory back pain, which can lead to structural and functional deficits as well as a decline in quality of life. Genetics plays an important role in ankylosing spondylitis occurrence, over 90% of patients with this condition have a particular genetic marker in their white blood cells, called HLA-B27. The HLA-B27 Ankylosing Spondylitis genetic marker appears to play a role in over 90% of the cases. The primary Ankylosing Spondylitis risk factors responsible for the development of the disease are age, gender, other genes, and heredity. Ankylosing Spondylitis life expectancy can be considered somewhat similar to that of the general population if the non-serious form of the disease is present, on the contrary patients who have the most severe forms of the disease can experience serious complications.
Early Ankylosing Spondylitis symptoms may include discomfort and stiffness in the lower back and hips, particularly in the morning and after periods of inactivity. Neck pain and fatigue are also prevalent. Signs of Ankylosing Spondylitis may intensify, improve, or cease at unpredictable periods throughout time.
Ankylosing Spondylitis diagnosis criteria might be challenging because the disorder progresses slowly and there is no definitive Ankylosing Spondylitis test. For Ankylosing Spondylitis, the modified New York classification is now utilized for both research and therapeutic purposes. Physical exam, individual medical history, and a family history of Ankylosing Spondylitis, as well as blood tests (including a test for HLA-B27), are factors responsible for Ankylosing Spondylitis diagnosis. Ankylosing Spondylitis x-ray is also an important tool for diagnosis.
Ankylosing Spondylitis Epidemiology Segmentation
As per DelveInsight, there was around 2.2 million Ankylosing Spondylitis prevalent population in the 7MM in 2021.
Among EU5 countries, Germany had the highest Ankylosing Spondylitis prevalence in 2021.
The Ankylosing Spondylitis Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Download the report to understand which factors are driving Ankylosing Spondylitis epidemiology trends at Ankylosing Spondylitis Epidemiological Insights
Ankylosing Spondylitis Treatment Market
There is no Ankylosing Spondylitis cure, however, therapies can alleviate Ankylosing Spondylitis symptoms and perhaps delay disease development. Recent research indicates that newer biologics for Ankylosing Spondylitis may be able to delay disease development in certain patients. Different people respond to different Ankylosing Spondylitis medications with varying levels of effectiveness. Thus, it may take time to find the most effective course of treatment for Ankylosing Spondylitis.
Ankylosing Spondylitis medications include Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Corticosteroids, Biologics, TNF Inhibitors, Interleukin Inhibitors, and pain medications.
Medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain are common Ankylosing Spondylitis treatment regimens for the various forms of spondyloarthritis. In extreme situations, posture-correction surgery may be considered. Ankylosing Spondylitis treatment options may differ depending on the kind of spondyloarthritis. In the case of psoriatic arthritis, for example, both the skin and the joint components must be addressed. Ankylosing Spondylitis medications may need to be changed in enteropathic arthritis (spondylitis/arthritis linked with inflammatory bowel disease) so that the gastrointestinal component of the disease is also addressed and not aggravated.
Furthermore, Ankylosing Spondylitis pipeline includes prospective monotherapies as well as combo treatments. Overall, the Ankylosing Spondylitis market is likely to grow further over the forecast period (2022–2032).
To know about more Ankylosing Spondylitis medications visit at Ankylosing Spondylitis Treatment
Ankylosing Spondylitis Pipeline Therapies and Key Companies
Ankylosing Spondylitis Market Dynamics
Certain efforts, such as Ankylosing Spondylitis Awareness Month in May, have been implemented by corporate and public sector groups to promote awareness of the condition. These initiatives will impact the growth of the Ankylosing Spondylitis market. In addition, pharmaceutical companies have increased their investments in drug research and development, thereby driving the Ankylosing Spondylitis market growth. Furthermore, newer, more novel therapies have been discovered to break the inflammatory cycle in Ankylosing Spondylitis by selectively targeting cytokines that cause inflammation, such as IL17A, thus, impacting the Ankylosing Spondylitis market positively. Moreover, the increase in Ankylosing Spondylitis prevalence will also create a lucrative opportunity for the Ankylosing Spondylitis market.
However, there is still an unmet need to identify individuals who may safely cease therapy. In addition, tumor necrosis factor inhibitor (TNFi) is a primary pharmacologic therapy that most people do not react to. These are among the major factors acting as a barrier to the Ankylosing Spondylitis market. Moreover, many years pass between the onset of symptoms and the diagnosis, and over-diagnosis is prevalent, thereby impeding the growth of the Ankylosing Spondylitis market.
Furthermore, the introduction of biosimilars into the Ankylosing Spondylitis market will raise competition and may stymie the Ankylosing Spondylitis market for both approved and future drugs if they are shown to be more effective and promising. It has also been noticed that enhanced regulatory systems are permitting and simplifying the approval of biosimilars. The approval of biosimilars will result in a decrease in sales, illustrating the rising possibility of significant income loss following the patent expiration of already approved drugs.
Scope of the Ankylosing Spondylitis Market Report
Discover more about the future Ankylosing Spondylitis market share of treatment therapies at New Drugs for Ankylosing Spondylitis
Table of Contents
Ankylosing Spondylitis Market Key Insights
Ankylosing Spondylitis Market Report Introduction
Ankylosing Spondylitis Market Overview at a Glance
Ankylosing Spondylitis Market Executive Summary
Disease Background and Overview
Ankylosing Spondylitis Treatment and Management
Ankylosing Spondylitis Epidemiology and Patient Population
Ankylosing Spondylitis Marketed Drugs
Ankylosing Spondylitis Emerging Drugs
7 Major Ankylosing Spondylitis Market Analysis
Ankylosing Spondylitis Market Outlook
Potential of Current and Emerging Therapies
Ankylosing Spondylitis Market Drivers
Ankylosing Spondylitis Market Barriers
Get in touch with our Business executive at Healthcare Due Diligence Services
Ankylosing Spondylitis Epidemiology
Ankylosing Spondylitis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Ankylosing Spondylitis epidemiology in the 7MM.
Ankylosing Spondylitis Pipeline
Ankylosing Spondylitis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ankylosing Spondylitis companies involved such as Fresenius Kabi, Shanghai Henlius Biotech, Pfizer, among others.
Ankylosing Spondylitis Market
Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ankylosing Spondylitis companies such as Pfizer, UCB Biopharma, among others.
Axial Spondyloarthritis Market
Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Axial Spondyloarthritis companies such as Eli Lilly and Company, Kyowa Kirin, AbbVie, among others.
Axial Spondyloarthritis Epidemiology
Axial Spondyloarthritis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Axial Spondyloarthritis epidemiology in the 7MM.
Axial Spondyloarthritis Pipeline
Axial Spondyloarthritis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Axial Spondyloarthritis companies involved such as Izana Bioscience, Kyowa Kirin Co. Ltd., Luye Pharma Group, among others.
Other Trending Reports
The Diabetes Market report delivers an in-depth understanding of the Diabetes, historical and forecasted epidemiology as well as the Diabetes market size and shares in the 7MM. Some of the key companies in the Diabetes Market include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and Others.
Type 2 Diabetes Market
The Type 2 Diabetes Market research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Type 2 Diabetes market size, share, and trends in the 7MM. Some of the key companies in the Type 2 Diabetes Market include Bayer, Eli Lilly and Company, Oramed and AstraZeneca, and Others.
Small Cell Lung Cancer Market
The Small Cell Lung Cancer (SCLC) Market report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market size, share, and trends in 7MM. Some of the key companies in the Small Cell Lung Cancer Market include Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics, and others.
Follicular Lymphoma Market
The Follicular Lymphoma Market research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Follicular Lymphoma market size, share, and trends in the 7MM. Some of the key companies in the Follicular Lymphoma Market include Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research Development, Novartis, MEI Pharma, BeiGene, and others.
Fragile X Syndrome (FXS) Market
The Fragile X Syndrome (FXS) Market report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market size, share, and trends in the 7MM. Some of the key companies in the Fragile X Syndrome (FXS) Market include Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, and others.
Related Healthcare Blogs
Ankylosing Spondylitis Treatment Market
Key Drugs in Pipeline for Autoimmune Diseases
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us Shruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com
SOURCE DelveInsight Business Research, LLP